Immunoproteomic analysis of Plasmodium falciparum antigens using sera from patients with clinical history of imported malaria

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Costa, Rita M ^a   Nogueira, Fátima ^a   De Sousa, Karina P ^a   Vitorino, Rui ^b   Silva, Marcelo S ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Antibody response; Imported malaria; Malaria antigens; Plasmodium falciparum

Indexed keywords

ELONGATION FACTOR 1ALPHA; GLUCOSE REGULATED PROTEIN 78; PARASITE ANTIBODY; PARASITE ANTIGEN; PHOSPHOGLYCERATE KINASE; PROTEIN DISULFIDE ISOMERASE;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALARIA; MASS SPECTROMETRY; MEDICAL HISTORY; MOLECULAR WEIGHT; PLASMODIUM FALCIPARUM;

ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; MALARIA, FALCIPARUM; MASS SPECTROMETRY; PLASMODIUM FALCIPARUM;

EID: 84875026266     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-100     Document Type: Article

References (27)

1. Malaria-an overview. Tuteja R, FEBS J 2007 274 4670 4679 10.1111/j.1742-4658.2007.05997.x 17824953 (Pubitemid 47353122)
2. WHO, World Malaria Report 2011 Geneva: World Health Organization/Global Malaria Programme 2011
3. WHO, World Malaria Report 2010 Geneva: World Health Organization/Global Malaria Programme 2010
4. Malaria in travellers. Epidemiology, disease and prevention. Kain KC, Keystone JS, Infect Dis Clin North Am 1998 12 267 284 10.1016/S0891-5520(05) 70005-2 9658245 (Pubitemid 28342428)
5. WHO, International travel and health, 2011-situation as on 1 January 2011. Malaria Geneva: World Health Organization 2011 23465712
6. Estatísticas de Saúde-Doenças de Declaração Obrigatória, 2004-2008 Available on line at: [ http://www.dgs.pt ] Accessed February 16, 2011 (in Portuguese) 22417579
7. Imported Plasmodium falciparum malaria: are patients originating from disease-endemic areas less likely to develop severe disease? A prospective, observational study. Jennings RM, DE Souza JB, Todd JE, Armstrong M, Flanagan KL, Riley EM, Dohert JF, AmJTrop Med Hyg 2006 75 1195 1199 (Pubitemid 351627507)
8. Immune effector mechanisms in malaria. Marsh K, Kinyanjui S, Parasit Immunol 2006 28 51 60 10.1111/j.1365-3024.2006.00808.x
9. Gamma-globulin and acquired immunity to human malaria. Cohen S, McGregor IA, Carrington S, Nature 1961 192 733 737 10.1038/192733a0 13880318
10. Treatment of East African P. falciparum malaria with West African human γ-globulin. McGregor IA, Carrington SP, Cohen S, Trans R Soc Trop Med Hyg 1963 57 170 175 10.1016/0035-9203(63)90058-0
11. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P, AmJTrop Med Hyg 1991 45 297 308
12. Antibodies from immune African donors with a protective effect in Plasmodium falciparum human infection are also able to control asexual blood forms of the parasite in Saimiri monkeys. Gysin J, Moisson P, Pereira da Silva L, Druilhe P, Res Immunol 1996 147 397 401 10.1016/0923-2494(96)82048-7 8903106 (Pubitemid 26335793)
13. A Recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. Genton B, Betula I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck H, Alpers MP, J Infect Dis 2002 185 820 827 10.1086/339342 11920300 (Pubitemid 34226210)
14. The future for blood-stage vaccines against malaria. Richards JS, Beeson JG, Immun Cell Biol 2009 87 377 390 10.1038/icb.2009.27
15. Human malaria parasites in continuous culture. Trager W, Jensen JB, Science 1976 193 673 675 10.1126/science.781840 781840
16. Culturing Plasmodium falciparum from finger-prick samples of infected blood. Thaithong S, Seugorn A, Beale GH, Trans Royal Soc Trop Med Hyg 1994 88 490 10.1016/0035-9203(94)90445-6 (Pubitemid 24264557)
17. Enzyme-Linked Immunosorbent Assay for measurement of cytomegalovirus glycoprotein B antidoby in serum. Hackett DJ, Zhang C, Stefanescu C, Pass RF, Clin Vac Immunol 2010 17 836 839 10.1128/CVI.00422-09
18. A proteomic view of the Plasmodium falciparum life cycle. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y, Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ, Nature 2002 419 520 526 10.1038/nature01107 12368866
19. Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Vaughan K, Blythe M, Greenbaum J, Zhang Q, Peters B, Doolan DL, Sette A, Paras Immunol 2009 31 78 97 10.1111/j.1365-3024.2008.01077.x
20. Malaria parasites contain two identical copies of an elongation factor 1 alpha gene. Vinkenoog RR, Sperança MA, van Breemen O, Ramesar J, Williamson DH, Ross-MacDonald PB, Thomas AW, Janse CJ, del Portillo HA, Waters AP, Mol Biochem Parasitol 1998 94 1 12 10.1016/S0166-6851(98)00035-8 9719506 (Pubitemid 28345144)
21. Malaria parasites lacking eef1a have a normal S/M phase yet grow more slowly due to a longer G1 phase. Janse CJ, Haghparast A, Sperança MA, Ramesar J, Kroeze H, del Portillo HA, Waters AP, Mol Microbiol 2003 50 1539 1551 10.1046/j.1365-2958.2003.03820.x 14651637 (Pubitemid 38010451)
22. Protein disulfide isomerase and host-pathogen interaction. Stolf BS, Smyrnias I, Lopes LR, Vendramin A, Goto H, Laurindo FRM, Shah AM, Santos CXC, Sci World J 2011 11 1749 1761
23. Crystal structure of Plasmodium falciparum phosphoglycerate kinase: evidence for anion binding in the basic patch. Smith CD, Chattopadhyay D, Pal B, Biochem Biophys Res Comm 2011 412 203 206 10.1016/j.bbrc.2011.07.045 21798238
24. Plasmodium falciparum gene encoding a protein similar to the 78-kDa rat glucose-regulated stress protein. Kumar N, Syin CA, Carter R, Quakyi I, Miller LH, PNAS 1988 85 6277 6281 10.1073/pnas.85.17.6277 3045815
25. Intimate molecular interactions of Plasmodium falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine design. Rodriguez LE, Curtidor H, Urquiza M, Cifuentes G, Reyes C, Patarroyo ME, Chem Rev 2008 108 3656 3705 10.1021/cr068407v 18710292
26. Conserved regions of the Plasmodium falciparum rhoptry-associated protein 3 mediate specific host-pathogen interactions during invasion of red blood cells. García J, Curtidor H, Vanegas M, Arévalo-Pinzon G, Patarroyo MA, Patarroyo ME, Peptides 2010 31 2165 2172 10.1016/j.peptides.2010. 09.002 20833215
27. A rhoptry antigen of Plasmodium falciparum contains conserved and variable epitopes recognized by inhibitory monoclonal antibodies. Schofield L, Bushell GR, Cooper JA, Saul AJ, Upcroft JA, Kidson C, Mol Biochem Parasitol 1986 18 183 195 10.1016/0166-6851(86)90037-X 2421161 (Pubitemid 16159899)